B1Q Stock Chart & Stats
€3.12
-€0.18(-5.30%)
At close: 4:00 PM EDT
€3.12
-€0.18(-5.30%)
Day’s Range― - ―
52-Week Range€1.37 - €4.13
Previous CloseN/A
Volume0.00
Average Volume (3M)203.00
Market Cap
€114.56M
Enterprise Value€63.07
Total Cash (Recent Filing)€6.71M
Total Debt (Recent Filing)€934.00K
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Aug 17, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding41,943,280
10 Day Avg. Volume609
30 Day Avg. Volume203
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-3.64
Price to Sales (P/S)47.35
P/FCF Ratio-4.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€34.46Price Target Upside1004.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.33
Revenue Forecast (FY)€12.18M
Bulls Say, Bears Say
Bulls Say
Manufacturing Scale & Regulatory ProgressA preliminary FDA bioequivalence determination plus validated blow-fill-seal production capable of ~1M units/week creates durable manufacturing advantage. High throughput and VAI reclassification reduce supply constraints, lower per-unit cost potential, and support rapid national launch and longer-term market share retention.
NRX-100 NDA Backed By Real-world EvidenceA submission model that pairs clinical trials with extensive RWE provides a structural regulatory and market access benefit. Broad RWE can strengthen label claims, support payer discussions, and shorten adoption cycles if FDA accepts the analytics approach, improving long-term commercial prospects beyond trial-only programs.
Improved Liquidity And Debt ReductionBecoming debt-free while completing multiple capital raises materially eases near-term financing pressure. Increased runway and reduced interest obligations improve capacity to execute regulatory filings, scale manufacturing and clinic rollout, and reduce forced-fire financing risk during key approval and launch windows.
Bears Say
Heavy Cash Burn & Negative EquitySustained large operating losses and negative equity signal an accumulated deficit and structural funding need. Ongoing negative free cash flow limits reinvestment capacity, increases dilution risk from future financings, and constrains flexibility to scale commercialization without persistent external capital.
Ongoing Dependence On External CapitalReliance on at-the-market equity programs and contingent clinic revenue is a structural vulnerability. Access to public equity can narrow or cost more if market conditions change, potentially delaying programs or forcing dilutive raises that affect long-term ownership, R&D pacing, and commercialization execution.
Commercial Channel & Market Execution RiskNeeding to establish two distinct go-to-market channels and displace entrenched compounding pharmacies imposes lasting execution costs. Payer, distributor and clinic adoption cycles are structural hurdles that can slow revenue scale, raise customer acquisition costs, and require sustained commercial investment.
NRX Pharmaceuticals News
B1Q FAQ
What was NRX Pharmaceuticals’s price range in the past 12 months?
NRX Pharmaceuticals lowest stock price was €1.37 and its highest was €4.13 in the past 12 months.
What is NRX Pharmaceuticals’s market cap?
NRX Pharmaceuticals’s market cap is €114.56M.
When is NRX Pharmaceuticals’s upcoming earnings report date?
NRX Pharmaceuticals’s upcoming earnings report date is Aug 17, 2026 which is in 11 days.
How were NRX Pharmaceuticals’s earnings last quarter?
NRX Pharmaceuticals released its earnings results on May 18, 2026. The company reported -€0.035 earnings per share for the quarter, missing the consensus estimate of €0.181 by -€0.215.
Is NRX Pharmaceuticals overvalued?
According to Wall Street analysts NRX Pharmaceuticals’s price is currently Undervalued.
Does NRX Pharmaceuticals pay dividends?
NRX Pharmaceuticals does not currently pay dividends.
What is NRX Pharmaceuticals’s EPS estimate?
NRX Pharmaceuticals’s EPS estimate is -0.09.
How many shares outstanding does NRX Pharmaceuticals have?
NRX Pharmaceuticals has 41,943,280 shares outstanding.
What happened to NRX Pharmaceuticals’s price movement after its last earnings report?
NRX Pharmaceuticals reported an EPS of -€0.035 in its last earnings report, missing expectations of €0.181. Following the earnings report the stock price went up 7.895%.
Which hedge fund is a major shareholder of NRX Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:B1Q
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NRX Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
158.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
56.82%
Trailing 12-Months
Company Description
NRX Pharmaceuticals
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
B1Q Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial forward progress across multiple fronts: near-term regulatory and manufacturing milestones for KETAFREE, an NRX-100 NDA supported by >65,000-patient RWE, FDA clearance to proceed with a sizable NRX-101 TMS augmentation trial (MIND1), expansion of HOPE clinics, and acquisition of Geneuro assets to broaden the pipeline. Financially, reported net loss improved materially (a 74% reduction year-over-year) and the company raised ~$7.0M post-quarter, while becoming debt-free. Counterbalancing these positives are near-term operational cash sensitivity, increased operating losses driven by higher R&D and G&A spend, ongoing regulatory timing risk, the need to build commercial channels (particularly to displace compounding pharmacy supply to clinics), and dependence on anticipated nondilutive funding for certain programs. Overall, the balance of concrete regulatory/operational advances and capital actions alongside manageable but material execution and timing risks supports a constructive outlook.View all DE:B1Q earnings summariesB1Q Stock 12 Month Forecast
Average Price Target
€34.46
▲(1004.49% Upside)
Technical Analysis
CervoMed
―
―
Werewolf Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―
CAMP4 Therapeutics Corporation
―